Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Interim Results

28 Sep 2005 10:01

ISIS Resources PLC28 September 2005 ISIS RESOURCES PLC Company No. 5375156 Interim Financial Reportfor the period ended 30 June 2005 Chairman's Statement 1 Independent Review Report 2 Profit and Loss Account 3 Balance Sheet 4 Cash Flow Report 5 Notes to the Interim Report 6-7 DIRECTORS, SECRETARY AND ADVISERS Directors Broker Craig Ian Burton (Chairman) Westhouse Securities LLP Josef El-Raghy Clements House Stuart Bottomley 14-18 Gresham Street London EC2V 7NN Registered Office and Directors' business address Nominated Adviser Adderbury Hill Barn RFC Corporate Finance Ltd Milton Road Level 8 Adderbury 250 St Georges Terrace Oxon OX17 3HN Perth WA 6000 Australia Secretary Auditors Katie Macdonald Keen EK & Co 2003 Ltd 12B Talisman Business Centre Bicester Oxon OX26 6HR Solicitors to the Company Principal Banker Watson, Farley & Williams Bankwest 15 Appold Street 1215 Hay Street, West Perth London EC2A 2HB Western Australia 6005 Registrars Computershare Investor Services PLC PO Box 82, The Pavilions Bridgewater Road Bristol BS99 7NH Phone: 0870 702 0000 ISIS RESOURCES PLC CHAIRMAN'S STATEMENT Welcome to the first Interim Report for Isis Resources Plc. Since your Companylisted on the AIM on March 30 this year, the Directors have reviewed a number ofinvestment and acquisition opportunities. At 30 June 2005 the Company had US$1.8m cash at bank. The Directors have focused on investment and acquisition opportunities in thenatural resources, mining service and technology sectors that would be suitableto the Company and shareholders. A potential investment may be either listed orunlisted and may be in companies, joint ventures, or direct ownership ofprojects. The Directors have continued to evaluate appropriate investmentopportunities for the Company from Africa, Europe and Australia. The Company currently has an experienced Board of three Directors who betweenthem have considerable investment and commercial expertise. The composition ofthe Board will be reviewed on a regular basis to ensure it has the appropriatemix of skills necessary for the objectives of the Company. Josef El-Raghy is the Managing Director of Centamin Egypt, which is dual listedon the Australian Stock Exchange and AIM. Stuart Bottomley worked as aportfolio manager for over 20 years, firstly with the Target Group of UnitTrusts and subsequently with Fidelity International. For the last 12 years hehas acted as a consultant to a number of private and public companies, with agrowing emphasis on the mining industry. I have 12 years experience specialising in venture capital in the resourcessector. Over that period I have successfully co-founded nine public listednatural resource companies, with projects in a wide variety of commodities andgeographic locations. I am currently a director of four resources companieslisted on the ASX, one of which is dual listed on AIM. In closing, on behalf of the Board I would like to thank you for your financialsupport and the interest shown by you in the Company. Yours sincerely Craig Burton Chairman INDEPENDENT REVIEW REPORT TO ISIS RESOURCES PLC Introduction We have been instructed by the company to review the financial information forthe six months ended 30 June 2005 set out on pages 3 to 7 and we have read theother information contained in the interim report and considered whether itcontains any apparent misstatements or material inconsistencies with thefinancial information. Our responsibilities do not extend to any otherinformation. Directors' responsibilities The interim report including the financial information contained therein is theresponsibility of, and has been approved by, the directors. The Directors areresponsible for preparing the interim report in accordance with the AIM Ruleswhich require that the accounting policies and presentation applied to theinterim figures should be consistent with those applied in preparing thepreceding annual accounts except where any changes, and the reasons for them,are disclosed. Review work performed We conducted our review in accordance with guidance contained in Bulletin 1999/4"Review of Interim Financial Information" issued by the Auditing Practices Boardfor use in the United Kingdom. A review consists primarily of making enquiriesof management and applying analytical procedures to the financial informationand underlying financial data and based thereon, assessing whether theaccounting policies and presentation have been consistently applied unlessotherwise disclosed. A review excludes audit procedures such as test of controlsand verification of assets, liabilities and transactions. It is substantiallyless in scope than an audit performed in accordance with United Kingdom auditingstandards and therefore provides a lower level of assurance than an audit.Accordingly, we do not express an audit opinion on the financial information. Review conclusion On the basis of our review we are not aware of any material modifications thatshould be made to the financial information as presented for the six monthsended 30 June 2005. EK & Co 2003 Ltd Chartered Certified Accountants 12B Talisman Business Centre Bicester Oxon OX26 6HR ISIS RESOURCES PLC PROFIT AND LOSS ACCOUNT FOR THE PERIOD ENDED 30 JUNE 2005 6 months to 30 June 2005 Note (unaudited) US$ Administration Expenses (39,647)Operating Loss (39,647)Net interest 23,949Loss on ordinary activities before taxation (15,698)Tax on loss on ordinary activities -Loss on ordinary activities after taxation (15,698)Equity Minority Interests -Loss retained and transferred from reserves (15,698)Basic loss per share (cents per share) 2 (0.0508)Diluted loss per share (cents per share) 2 (0.0456) Statement of Total Recognised Gains and LossesLoss for the financial period (15,698)Exchange loss on foreign currency net inventories (19,287) Total recognised loss for the period (34,985) All transactions arise from continuing operations ISIS RESOURCES PLC BALANCE SHEET AS AT 30 JUNE 2005 At 30 June 2005 Note (unaudited) US$Fixed AssetsIntangible assets 0 0Current AssetsCash assets 1,806,430Receivables 3,556 1,809,986 Creditors: amounts falling due within one year (13,239) Net current assets 1,796,747 Total assets less current liabilities 1,796,747 Capital and reservesCalled up share capital 90,240Share premium account 1,741,492Profit and loss account (34,985)Shareholders Funds 5 1,796,747 ISIS RESOURCES PLC CASHFLOW STATEMENT FOR THE PERIOD ENDED 30 JUNE 2005 6 months to Note 30 June 2005 US$ Net cash inflow from operating activities 3 (49,251) Return on Investments and servicing of financeInterest received 23,949Net cash inflow from returns on Investments and servicing of 23,949finance Taxation - Capital expenditure and financial investmentPurchase of intangible fixed assets -Net cash outflow from capital expenditure and financial investment - Management of liquid resourcesShort term deposits - Net cash inflow before financing (25,302) FinancingIssue of shares 1,915,213Share issue costs (83,481)Net cash inflow from financing 1,831,732 Increase in cash 4 1,806,430 ISIS RESOURCES PLC NOTES TO THE INTERIM REPORT FOR THE PERIOD ENDED 30 JUNE 2005 1 Basis of Preparation of Financial Statements The interim financial information set out on pages 3 to 7 has been prepared onthe same basis and using the same accounting policies as will be applied inpreparing the accounts for the period ended 31 December 2005, the company'sfirst period end. The financial statements have been prepared under the historical cost convention Transactions of UK companies denominated in foreign currencies are translatedinto sterling at the rates ruling at the dates of the transactions. Amountsreceivable and payable in foreign currencies at the balance sheet date aretranslated at the rates ruling at that date. The financial information for the 6 months ended 30 June 2005 is unaudited. Inthe opinion of the directors the financial information for these periods fairlypresents the financial position, results of operations and cash flows for thoseperiods and conform with generally accept account principles. This is the first interim report for Isis Resources for the period fromincorporation 24 February 2005 to 30 June 2005. The functional currency of the Group is United States dollars (US$). Thisrepresents the currency of the primary economic environment in which the Groupoperates. The Interim report has been prepared in US$. 2 Loss Per Share The calculation of the loss per share is based on a loss of $15,698 to 30 June2005 and the weighted average number of ordinary shares outstanding of30,920,635 at 30 June 2005. The diluted earnings per share is based on aweighted average number of shares outstanding of 34,412,699 and the loss pershare presented. 3 Net Cash Outflow from Operating Activities 6 months to 30 June 2005 (unaudited) US$Operating loss (39,647)Increase in debtors (3,556)Increase in creditors 13,239Foreign exchange loss (19,287) Net cash inflow from operating activities (49,251) 4 Reconciliation of Net Cash Flows to Movement in Net Funds 6 months to 30 June 2005 (unaudited) US$ Increase in cash in the period 1,806,430Cash (outflow)/inflow from financing - short term - 1,806,430 Net funds at beginning of period -Net funds at end of period 1,806,430 5 Reconciliation of Movements in Shareholders Funds Loss for the period (15,698)Exchange loss on foreign currency net investments (19,287)New share capital subscribed 1,915,213Costs of Capital (83,481)Net increase in shareholders funds 1,796,747 6 Publication of Non-statutory Accounts The financial information set out in this interim report does not constitutestatutory accounts as defined in section 240 of the Companies Act 1985. Theauditors' report on these financial statements was unqualified and did notcontain a statement under Section 237(2) of the Companies Act 1985 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20207:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
28th Oct 202011:01 amGNWVerona Pharma plc : Update on AIM Delisting
23rd Oct 20205:30 pmRNSVerona Pharma
22nd Oct 20207:00 amGNWVerona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update
13th Oct 20207:00 amGNWVerona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020
23rd Sep 20209:06 amGNWVerona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD
21st Sep 20207:00 amGNWIntended Delisting and Cancellation of Ordinary Shares from Trading on AIM
17th Sep 20207:00 amGNWVerona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing
16th Sep 20201:25 pmGNWVerona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease
8th Sep 20207:00 amGNWVerona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
2nd Sep 20207:00 amGNWVerona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference
26th Aug 202010:19 amGNWVerona Pharma plc: Grant of RADSUs and PDMR Dealings
24th Aug 20207:00 amGNWVerona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020
19th Aug 20207:00 amGNWVerona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
14th Aug 20207:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020
7th Aug 20203:46 pmGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
4th Aug 20206:13 pmGNWVerona Pharma plc: Issue of Equity, PDMR Dealings & Total Voting Rights
3rd Aug 20207:00 amGNWVerona Pharma Announces August 2020 Virtual Investor Conference Participation
30th Jul 202010:52 amGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
30th Jul 20207:00 amGNWVerona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update
27th Jul 20207:01 amGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
22nd Jul 20204:50 pmGNWClosing of Financing, Issued Share Capital and Total Voting Rights
17th Jul 20205:47 pmGNWVerona Pharma plc: PDMR Dealings
17th Jul 20207:00 amGNWVerona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription
6th Jul 20204:04 pmGNWVerona Pharma plc: Issue of Equity and Total Voting Rights
14th May 20207:00 amGNWVerona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program
12th May 20201:11 pmGNWDirector/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings
1st May 20205:12 pmGNWVerona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference
30th Apr 20207:00 amGNWVerona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020
23rd Apr 20207:00 amGNWVerona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update
16th Apr 202012:12 pmGNWVerona Pharma plc: Results of AGM
8th Apr 20207:00 amGNWUpdate on AGM Procedure
31st Mar 20207:00 amGNWVerona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD
20th Mar 202011:28 amGNWVerona Pharma plc: Issue of Equity and Total Voting Rights
17th Mar 20202:06 pmRNSSecond Price Monitoring Extn
17th Mar 20202:01 pmRNSPrice Monitoring Extension
16th Mar 20205:13 pmGNW2019 Annual Report and Accounts and Notice of AGM
5th Mar 20204:01 pmGNWGrant of Restricted Stock Units and PDMR Dealings
27th Feb 20207:00 amGNWVerona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update
21st Feb 20207:00 amGNWVerona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update
14th Feb 20207:00 amGNWVerona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
7th Feb 20207:00 amGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
3rd Feb 20207:00 amGNWVerona Pharma Announces Senior Management Changes
28th Jan 20207:00 amGNWVerona Pharma to Present at LSX World Congress 2020
17th Jan 20201:06 pmGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 20205:00 amGNWVerona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.